New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 1, 2014
07:09 EDTSHPGShire reports Q1 EPS $2.36, consensus $2.22
Reports Q1 revenue $1.35B, consensus $1.38B. Shire said, "We'll shortly be meeting with the FDA to determine our next steps with lifitegrast. We continue to advance our intrathecal enzyme replacement therapy program for rare pediatric CNS diseases. In addition, the ViroPharma acquisition brought us the Phase 2 program for maribavir, an investigational treatment under development for cytomegalovirus infection in transplant patients, as well as several potential new uses for CINRYZE. And, our acquisition of Fibrotech adds FT011, a small molecule targeting an innovative, novel mechanism of action, currently in a Phase 1B study in patients with renal impairment, and a Phase 2 study in patients with FSGS, a rare kidney disease, is planned."
News For SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 25, 2015
13:58 EDTSHPGShire initiated with a Reduce at HSBC
Price target GBP 47.34.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use